Type 2 Inflammation in CSU: Emerging Evidence and Implications
Prof. Marcus Maurer explores novel CSU therapies, shedding light on unique inflammatory pathways and emerging treatment data.
Learning objectives
- Highlight the central role of skin mast cells in the pathophysiology of chronic spontaneous urticaria (CSU)
- Delve into the role of type 2 inflammation in driving mast cell activation and neurogenic inflammation in the pathogenesis of CSU
- Explore how investigational CSU therapeutics improve our understanding of CSU
Description
In this ADVENT medical symposium at the GA2LEN Global Urticaria Forum, Prof. Marcus Maurer illuminated the pivotal role played by skin mast cells in CSU pathophysiology, highlighting their involvement in the condition's development. This presentation also explored the influence of type 2 inflammation in activating mast cells and inducing neurogenic inflammation, contributing to our understanding of CSU’s underlying mechanisms. Furthermore, the presentation explored investigational CSU therapeutics and their impact on improving our understanding of this complex condition, offering a comprehensive overview of the ongoing efforts to manage and decipher CSU.
Related resources
